Summit Therapeutics Inc.
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information.
Subsequent Events.
On November 4, 2026, the Company entered into the 2026 Sublease Agreement with Genius, an affiliate of the Company’s Co-CEO, Robert W. Duggan. Pursuant to the 2026 Genius Sublease Agreement, effective November 1, 2026, the Company sublet from Genius 2,382 square feet of office space in the same facility as the Company’s headquarters in Miami, Florida for a twelve month term for a total rental payment of approximately $205.
10b5-1 Trading Plans.
None.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.